MYLK2

Across TCGA pan-cancer cohorts, MYLK2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MYLK2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MYLK2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYLK2 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC and HNSC are the cancer types where MYLK2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYLK2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	III,IV	−2.908	<.001	9	view →
HNSC	All	All	−1.139	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

MYLK2–PDAC

Open the PDAC breakdown →